Parabolic Drugs said on Monday it has received a certificate of suitability (COS) for its key molecule Cefixime in the European Union.
The COS would enable the company to expand its presence in regulated markets, it said in a statement to the National Stock Exchange.
Cefixime, an oral third generation cephalosporin antibiotic, has a global market size of USD 839 million, growing at 20.9% annually and is used in the treatment of gonorrhea, tonsilitis and pharyngitis, it added.
The European market contributes to over 18% in total sales for this molecule, it said.
At 10.47 am, shares in the firm were up 3.6% at Rs 48.5 in a firm Mumbai market.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
